SUR-5 Inhibitors
SUR-5 Inhibitors pertains to a group of chemicals designed to intervene with the PI3K/AKT/mTOR signaling cascade. The rationale for their selection is based on the assumed involvement of SUR-5 within this cellular signaling mechanism. These chemicals manifest their effects at various junctures within the signaling pathway, ensuring versatile modulation.
For instance, Wortmannin and LY294002, acting as PI3K inhibitors, curtail the activation of downstream AKT, a critical mediator in this signaling network. Similarly, Rapamycin and its derivative Temsirolimus specifically thwart mTOR, thereby negating its downstream effects. Dual inhibitors, like NVP-BEZ235, exhibit a broader inhibitory spectrum by simultaneously targeting PI3K and mTOR. On the other hand, specific AKT inhibitors such as MK-2206 and AZD5363 curtail AKT activation directly, disrupting its consequential actions in the pathway. The diverse modes of action embodied by these chemicals accentuate the intricacy of the PI3K/AKT/mTOR signaling system and the strategic points at which it can be modulated. T
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin can inhibit PI3K, leading to decreased AKT phosphorylation and activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents AKT activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a downstream effector in the PI3K/AKT pathway. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
NVP-BEZ235 inhibits both PI3K and mTOR, affecting multiple nodes in the pathway. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an AKT inhibitor that disrupts AKT membrane recruitment. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 directly inhibits AKT activation and its subsequent actions. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor, specifically targeting mTORC1. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is a potent inhibitor of all AKT isoforms. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Idelalisib inhibits PI3K delta isoform, modulating the PI3K/AKT pathway in specific cell types. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
Buparlisib is a pan-PI3K inhibitor, blocking the activation of all PI3K isoforms. | ||||||